Overview

Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
0
Participant gender:
All
Summary
The primary objective of this study is to demonstrate the efficacy of T1225 eye drops versus placebo eye drops on the global ocular discomfort (VAS).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Laboratoires Thea
Collaborators:
Keyrus
Keyrus Biopharma
VEEDA
Treatments:
Azithromycin
Ophthalmic Solutions
Povidone
Tetrahydrozoline
Criteria
Inclusion Criteria:

-Diagnosis of moderate to severe chronic blepharitis (posterior and/or anterior) in at
least one eligible eye

Exclusion Criteria:

- Monophtalmia

- Eyelid dysfunction

- Facial paralysis.

- Severe dry eye syndrome.

- Ocular metaplasia.

- Filamentous keratitis

- Schirmer test < 5 mm.

- Best far corrected visual acuity < 1/10.